Becaplermin
Human Platelet-derived Growth Factor — ALIMENTARY TRACT AND METABOLISM
Also known as: regranex, rhPDGF-BB, RWJ 60235, RWJ-60235
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Becaplermin is a drug in the Human Platelet-derived Growth Factor class catalogued in DrugCentral. It was first approved by the FDA in 1997. DrugCentral lists 1 molecular target, including PDGFRB|PDGFRA. Recorded indications include Neuropathic diabetic ulcer - foot.
- Drug class: Human Platelet-derived Growth Factor.
- Molecular targets: PDGFRB|PDGFRA (1 listed in DrugCentral).
- Indications: Neuropathic diabetic ulcer - foot.
- ATC code: A01AD08 (Other agents for local oral treatment).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Neuropathic diabetic ulcer - foot
Mechanism & targets
| Established pharmacologic class | Human Platelet-derived Growth Factor |
|---|
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Platelet-derived growth factor receptor | PDGFRB|PDGFRA | agonist | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1997-12-16 | FDA | — | OMJ PHARMACEUTICALS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A01AD08 | ALIMENTARY TRACT AND METABOLISM › STOMATOLOGICAL PREPARATIONS › STOMATOLOGICAL PREPARATIONS › Other agents for local oral treatment |
D03AX06 | DERMATOLOGICALS › PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS › CICATRIZANTS › Other cicatrizants |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Wound complication | 455.4 |
| Osteomyelitis | 256.9 |
| Toe amputation | 217.0 |
| Cellulitis | 129.7 |
| Application site infection | 118.0 |
| Application site pain | 98.0 |
| Wound infection staphylococcal | 76.7 |
| Wound secretion | 61.8 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Becaplermin used for?
DrugCentral lists the following indications for Becaplermin: Neuropathic diabetic ulcer - foot.
How does Becaplermin work?
Its molecular targets in DrugCentral include PDGFRB|PDGFRA (agonist).
When was Becaplermin first approved?
Becaplermin was first approved by the FDA in 1997.
What drug class does Becaplermin belong to?
Becaplermin is in the Human Platelet-derived Growth Factor class.
Browse: all drugs starting with B · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4925 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201556 — compound record and bioactivity
- DrugBank DB00102 — drug record
- FDA UNII 1B56C968OA — substance identity
- DailyMed: FDA labels for Becaplermin — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.